Anti-Human CD33 Recombinant Nanobody (SAA2052) (HB185013)

Name: Anti-Human CD33 Recombinant Nanobody (SAA2052)
Brand: abinScience
SKU: HB185013
Price: 191 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

50ug
100ug
1mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HB185013

Description

Anti-Human CD33 Nanobody (SAA2052) [SAA2052] (HB185013) is a alpaca monoclonal antibody detecting CD33 in ELISA, FCM. Suitable for Human and Cynomolgus.

Highlights

●Flow Cytometry — Validated for flow cytometry applications.

Species reactivity

Human, Macaca fascicularis (Crab-eating macaque) (Cynomolgus monkey)

Applications

ELISA, FCM, WB

Host species

Alpaca

Isotype

VHH-8His-Cys-tag

Clone ID

SAA2052

Clonality

Monoclonal

Tested applications

Target

Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P20138

Form

Liquid

Storage buffer

0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg).

1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343

2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212

3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323

4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872

5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109

6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905

7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955

8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798

Note

For research use only.

Images

SDS-PAGE

SDS-PAGE for Anti-Human CD33 Recombinant Nanobody (SAA2052)
Bioactivity

Detects CD33 (Catalog No: HB185011) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-CD33 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD33 (Catalog No: HB185011)